Innate Pharma (IPHA) Stock Analysis: AI Score & Alternative Data
Alt-data signals are cooling for Innate Pharma
Is Innate Pharma a buy right now? The alternative data says hold. This IPHA stock analysis is built on the 25+ alternative data signals AltIndex tracks on Innate Pharma every day — hiring, web traffic, sentiment, social reach — rolled into an AI Score of 42/100: a Hold. The stock trades at $1.62 with a $181M market cap.
The soft spots over the past 90 days: web traffic down 5.4% to 14K monthly visits, headcount (according to LinkedIn) down 5.1% to 168 employees, and just 44% of employees report a positive business outlook. The rest of the signal set is holding steady, which keeps IPHA at a hold rather than a sell.
IPHA’s broader alt-data profile also covers X followers (4K), and sentiment (100/100). Every signal links to its own page with full history, the IPHA technical analysis covers RSI, moving averages, and support and resistance, and the full table of everything AltIndex tracks on IPHA is just below.
Innate Pharma AI Stock Analysis
Innate Pharma is a biotechnology company dedicated to the discovery, development, and commercialization of first-in-class therapeutic antibodies that harness the innate immune system to improve the treatment of cancer. With a history of innovation and strategic partnerships, Innate Pharma has positioned itself as a key player in the oncology space.
Analysis generated October 1, 2026.
Recent Innate Pharma Stock Alerts
|
Innate Pharma | October 9 Price is up by 8.4% in the last 24h. |
|
Innate Pharma | October 5 Price is up by 8.1% in the last 24h. |
|
Innate Pharma | October 2 Price is up by 6.3% in the last 24h. |
|
Innate Pharma | September 30 Price is up by 11.3% in the last 24h. |
Innate Pharma Alternative Data
| Alternative Data | Value | 3m Change | Trend |
|---|---|---|---|
| Webpage Traffic | 14K | 5.4% | |
| Job Posts | 0 | N/A | |
| LinkedIn Employees | 168 | 5.1% | |
| Employee Recommend | 94 | 0% | |
| Business Outlook | 44 | 0% | |
| Sentiment | 100 | 0% | |
| Reddit Mentions | 0 | N/A | |
| X Mentions | 3 | N/A | |
| Stocktwits Mentions | 0 | N/A | |
| News Mentions | 0 | N/A | |
| Stocktwits Subscribers | 2K | 0.9% | |
| X Followers | 4K | 0% |
About Innate Pharma (IPHA)
Innate Pharma SA, a biotechnology company, discovers, develops and markets therapeutic antibodies for the treatment of oncological indications in France and internationally. The company is headquartered in Marseille, France.
| Price | $1.62 |
| Target Price | $387.74 |
| Volume | 63,420,177 |
| Market Cap | $181M |
| Year Range | $1 – $3 |
| Dividend Yield | 0% |
| PE Ratio | — |
| Analyst Rating | 38% buy |
| Industry | Biotechnology |
Latest Innate Pharma News
View more → |
Innate Pharma Q2 Earnings Call HighlightsSeptember 17 - MarketBeat |
 |
Innate Pharma Secures €30M, Extends Cash Runway Into 2028August 14 - Biztoc.com |
Sobi enters strategic partnership with Innate Pharma to license lacutamab in T-cell lymphomaAugust 9 - PRNewswire |
|
 |
Innate Pharma concludes enrolment in dose escalation of IPH4502 studyJuly 22 - Biztoc.com |
Sobi and Innate announce partnership is now effective following completion of closing conditionsSeptember 16 - PRNewswire |
|
See Innate Pharma’s complete price and AI Score history
Sign up to unlock 1-year and all-time charts for IPHA, plus 25+ alternative data signals, AI Scores, and real-time alerts.
Get Started for FREEInnate Pharma Earnings & Financial Performance
View all earnings →Innate Pharma Insider Trading Activity
View all →| No recent insider transactions on file. |
Innate Pharma Congress Trading
View all →| Politician | Filing Date | Type | Size |
|---|---|---|---|
| No congress trades on file. | |||
Stocks Similar to Innate Pharma
See all →
Explore Innate Pharma Data
Frequently Asked Questions: Innate Pharma (IPHA)
Innate Pharma has an AltIndex AI Score of 42/100 (Hold). The score reflects mixed alternative data signals. All investments carry risk.
42/100. The AI Score combines 25+ alternative data signals including job postings, employee sentiment, social media, web traffic, and financials. Scores above 60 = buy, 40–59 = hold, below 40 = sell. Updated daily.
Currently, the price of one share of Innate Pharma (IPHA) stock is $1.62 with a market cap of $181M.
As of today, Innate Pharma’s PE (Price to Earnings) ratio is —.
View the latest Innate Pharma insider transactions to see recent buying and selling activity by company executives and directors.
Check the Innate Pharma congress trading page for the latest disclosed trades by U.S. senators and representatives.
AltIndex tracks 25+ signals including job postings, web traffic, employee sentiment, Reddit mentions, Stocktwits activity, insider transactions, congressional trades, Google Trends, app downloads, and more.
The IPHA stock price chart above shows Innate Pharma’s performance over time alongside its AI Score. Investors can identify patterns, trends, and potential support or resistance levels. View the full Innate Pharma technical analysis for RSI, moving averages, and more.
See the stocks similar to Innate Pharma section on this page for companies in the same industry ranked by market cap and AI Score.
